Lv4
480 积分 2024-09-05 加入
Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial
9小时前
待确认
Who Classification of Endocrine and Neuroendocrine Tumours, 5th Edition - Who Classification of Tumours, Volume 10
9天前
已关闭
Who Classification of Endocrine and Neuroendocrine Tumours, 5th Edition - Who Classification of Tumours, Volume 10
9天前
已关闭
Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases
11天前
已完结
Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases
11天前
已完结
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
14天前
已完结
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses
27天前
已完结
LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)
27天前
已完结
Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
1个月前
已完结
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
1个月前
已完结
皖公网安备34019202002308
